Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud
This article was originally published in The Tan Sheet
Executive Summary
Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction
You may also be interested in...
DOJ To Expand Use Of False Claims Act To Manufacturing And AER Violations
Drug manufacturers that sell to the government products that do not meet specifications or that fail to report serious adverse events could face False Claims Act allegations and potentially severe penalties in the near future
Leiner Files For Chapter 11 Protection, Explores Selling Business
Leiner Health Products' shutdown of its U.S. OTC operations a year ago forced the firm to seek Chapter 11 bankruptcy protection and explore selling its U.S. business
Leiner Asks FDA About Restarting U.S. OTC Operations, Posts $27.5 Mil. Loss
Heightened concerns over product quality triggered by adulterated Chinese imports and the need for more than one U.S. private-label supplier are fueling Leiner Health Products' optimism as it prepares to reenter the OTC market and recover from setbacks that led to a $27.5 million net loss in its latest quarter, CEO Robert Kaminski said Aug. 14